GSK's acquisition of Nuvalent, Inc. is a strategic move to bolster its oncology portfolio. The deal includes two late-stage, potential best-in-class ROS1 and ALK inhibitors for non-small cell lung cancer (NSCLC), currently under US FDA review for 2026 approvals. This acquisition accelerates GSK's entry into lung cancer, providing a platform for expansion with Ris-Rez, GSK’s B7-H3 antibody-drug conjugate (ADC).
The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, inclusive of synergies and reprioritisation. Zidesamtinib and neladalkib, the two lead products, aim for longer effective treatment with better quality of life through high target-selectivity, durable treatment response, improved tolerability, enhanced blood-brain barrier penetration for tumour spread, and broader coverage of ALK and ROS1 mutations, potentially addressing efficacy and/or tolerability limitations of existing therapies.
Nuvalent's expertise in chemistry and structure-based drug design, coupled with its close collaboration with leading physician-scientists and patient advocates, has driven remarkable enrolment, accelerating development and building confidence in the clinical profile of these drugs. GSK's proven track record, infrastructure, and expertise will support the successful commercialisation of zidesamtinib and neladalkib, as well as accelerate advancement of Nuvalent's broader discovery pipeline.
However, the acquisition is not without its risks. The transaction is subject to customary closing conditions, including the tender of a majority of Nuvalent’s outstanding shares of Class A common stock in the tender offer and the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act in the US. GSK must also account for the transaction as a business combination and assume Nuvalent’s existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield.
In conclusion, GSK's acquisition of Nuvalent is a strategic move that has the potential to significantly enhance its oncology portfolio. However, the deal is not without its risks, and GSK must carefully navigate the closing conditions and revenue-sharing arrangements to ensure a successful integration.
